Clinical case of sequential endoprosthesis replacement of large joints with subsequent removal of pseudotumor elbow in a patient with severe hemophilia A

DOI: https://doi.org/10.29296/25877305-2019-06-19
Download full text PDF
Issue: 
6
Year: 
2019

Professor V. Zorenko(1), MD; T. Polyanskaya(1), Candidate of Medical Sciences; E. Karpov(1); N. Sadykova(1), Candidate of Medical Sciences; A. Koroleva(1); A. Shuster(2), Candidate of Biological Sciences; Professor D. Kudlay2, MD; A. Borozinets(2), Candidate of Medical Sciences 1-National Medical Research Center of Hematology, Moscow 2-JSC «GENERIUM», Moscow

A specific feature of hemophilia, unlike many other hemorrhagic diathesis, is the defeat of the musculoskeletal system due to repeated bleedings. First described clinical case of the effective application of recombinant coagulation factor VIII (Octofactor, moroctocog alpha, JSC «GENERIUM») in a patient with hemophilia A during performing a series of sequential prosthetics of major joints. The use of moroctocog alpha in the required doses provides adequate hemostasis during surgery, as well as contributes to the favorable course of the postoperative period and timely discharge of the patient.
Keywords: 
hematology
hemophilia A
moroctocog alpha
deforming arthrosis
pseudotumor
endoprosthesis joint replacement

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Stonebraker J., Bolton-Maggs P., Soucie J. et al. A study of variations in the reported haemophilia A prevalence around the world // Haemophilia. – 2010; 16 (1): 20–32.
  2. Rukovodstvo po lecheniju gemofilii. 2-e izd. / Monreal': Izdanie VFG, 2012; 74 s. [Guidelines for the Management of Hemophilia. 2nd ed. / Montreal6 WFG, 2012; 74 p.] Rezhim dostupa / Access Mode: http://www1.wfh.org/publication/files/pdf-1531.pdf. DOI: 10.1111/j.1365-2516.2012.02909.x
  3. Report on the Annual Global Survey, 2017. World Federation of Hemophilia, Canada; 2018. 80 p.
  4. Andreev Ju.N. Mnogolikaja gemofilija / M.: N'judiamed., 2006; 232 c. [Andreev Yu. N. The many faces of hemophilia / M.: Newdiamed., 2006; 232 s. (in Russ.)].
  5. Gilbert M. Reconstructive surgery in the hemophiliae // Mt. Sin. J. Med. – 1977; 44 (3): 374–88.
  6. Kuznik B.I., Sturov V.G., Levshin N.Ju. i dr. Gemorragicheskie i tromboticheskie zabolevanija i sindromy u detej i podrostkov: Patogenez, klinika, diagnostika, terapija i profilaktika. 2-e izd., pererab. i dop. / Novosibirsk: Nauka, 2018; 524 s. [Kuznik B.I., Sturov V.G., Levshin N.Yu. et al. Hemorrhagic and thrombotic diseases and syndromes in children and adolescents: Pathogenesis, clinic, diagnostics, treatment and prevention. 2nd ed., pererab. i dop. / Novosibirsk: Nauka, 2018; 524 p. (in Russ.)].
  7. Srivastava A., Brewer A., Mauser-Bunschoten E. et al. Guidelines for the management of hemophilia (WFH) // Haemophilia. – 2013; 19: e1–e47.
  8. Protokol vedenija bol'nyh. «Gemofilija» // Problemy standartizatsii v zdravoohranenii. – 2006; 18–74 [Protocol of management of patients with «Hemophilia» // Problems of standardization in health care. – 2006; 18–74 (in Russ.)].
  9. Gosudarstvennaja programma «Razvitie farmatsevticheskoj i meditsinskoj promyshlennosti» na 2013–2020 gody [Elektronnyj resurs]: Osnovnye dannye po gosudarstvennoj programme «Razvitie farmatsevticheskoj i meditsinskoj promyshlennosti» na 2013–2020 gody / M.: Minpromtorg Rossii, 2014 [State program «Development of pharmaceutical and medical industry» for 2013-2020 [Electronic resource]: Basic data on the state program «Development of pharmaceutical and medical industry» for 2013–2020 / M.: Ministry Of Industry And Trade, 2014 (in Russ.)]. Rezhim dostupa / Access mode: http://minpromtorg.gov.ru/common/upload/files/docs/MinProm_02.06.14.pdf.
  10. Kudlaj D.A. Razrabotka i primenenie otechestvennyh rekombinantnyh preparatov faktorov svertyvanija krovi VII, VIII, IX u detej s gemofiliej A i B // Pediatrija. Zhurnal im. G.N. Speranskogo. – 2019; 98 (1): 9–17 [Kudlay D.A. Development and use of Russian recombinant blood coagulation factor VII, VIII, IX drugs in children with hemophilia A and B // Pediatriya. Zhurnal im. G.N. Speranskogo. – 2019; 98 (1): 9–17 (in Russ.)].
  11. Zorenko V.Ju., Mishin G.V., Severova T.V. i dr. Farmakokineticheskie svojstva, bezopasnost' i perenosimost' preparata Oktofaktor (rezul'taty I fazy klinicheskogo issledovanija u bol'nyh gemofiliej A) // Vopr. gematol., onkol. i immunopatol. v pediat. – 2013; 12 (2): 30–7 [Zorenko V.Yu., Mishin G.V., Severova T.V. et al. Pharmacokinetics, safety, and tolerability of Octofactor in patients with hemophilia A: Results of phase I clinical study // Voprosy gematologii/onkologii i immunopatologii v pediatrii. – 2013; 12 (2): 30–7 (in Russ.)].
  12. Davydkin I.L., Andreeva T.A., Zorenko V.Ju. i dr. Effektivnost' i bezopasnost' preparata Oktofaktor pri profilakticheskom lechenii bol'nyh s tjazheloj i srednetjazheloj formoj gemofilii A (rezul'taty 1-j chasti klinicheskogo issledovanija II–III fazy) // Vopr. gematol., onkol. i immunopatol. v pediat. – 2013; 12 (3): 29–37 [Davydkin I.L., Andreeva, T.A., Zorenko V.Yu. et al. Efficiency and safety of Octofactor in prevention of bleeding episodes in patients with severe and moderate hemophilia A: Results of part 1 of phase II–III clinical trial // Voprosy gematologii/onkologii i immunopatologii v pediatrii. – 2013; 12 (3): 29–37 (in Russ.)].
  13. Andreeva T.A., Zorenko V.Ju., Davydkin I.L. i dr. Effektivnost' i bezopasnost' preparata Oktofaktor v lechenii bol'nyh s tjazheloj i srednetjazheloj formoj gemofilii A (rezul'taty 2-j chasti klinicheskogo issledovanija II–III fazy) // Vopr. gematol., onkol. i immunopatol. v pediat. – 2013; 12 (4): 31–7 [Andreeva T.A., Zorenko V.Yu., Davydkin I.L. et al. Efficiency and safety of Octofactor in the treatment of patients with severe and moderate hemophilia A: Results of part 2 of phase II–III clinical trial // Voprosy gematologii/onkologii i immunopatologii v pediatrii. – 2013; 12 (4): 31–7 (in Russ.)].
  14. Shiller E., Vdovin V., Petrov V. et al. Safety and efficacy of new moroctocog alfa drug (Octofactor) in prophylactic treatment in adolescent patients with severe and moderate hemophilia A // Blood. – 2015; 126 (23): 4703.
  15. Pravila provedenija issledovanij biologicheskih lekarstvennyh sredstv Evrazijskogo ekonomicheskogo sojuza, 2016; 714 s. [Rules of research of biological medicines of the Eurasian economic Union, 2016; 714 c. (in Russ)]. Rezhim dostupa / Access mode: https://docs.eaeunion.org/docs/ru-ru/01411954/cncd_21112016_89
  16. Ivanov R., Sekareva G., Kravtsova O. i dr. Pravila provedenija issledovanij bioanalogovyh lekarstvennyh sredstv (bioanalogov) // Farmakokinetika i farmakodinamika. – 2014; 1: 21–36 [Ivanov R., Sekareva G., Kravtsova O. et al. Guidelines of research biosimilar drugs // Farmakokinetika i farmakodinamika. – 2014; 1: 21–36 (in Russ.)].
  17. Mamaev A.N., Kudlaj D.A. Vizualizatsija dannyh v prezentatsijah, otchetah i issledovanijah / M.: Prakticheskaja meditsina, 2011; 39 s. [Mamaev A.N., Kudlay D.A. Visualize data in presentations, reports, and studies / M.: Prakticheskaya medicina, 2011; 39 s. (in Russ.)]